Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

hVIVO (HVO) Share Price

Price 17.50p on 09-05-2025 at 04:45:11
Change 0.00p 0%
Buy 18.00p
Sell 17.00p
Buy / Sell HVO Shares
Last Trade: Sell 15,000.00 at 17.484p
Day's Volume: 0
Last Close: 17.50p
Open: 0.00p
ISIN: GB00B9275X97
Day's Range 0.00p - 0.00p
52wk Range: 12.60p - 30.60p
Market Capitalisation: £120m
VWAP: 0.00p
Shares in Issue: 687m

hVIVO (HVO) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 15,000 17.484p Ordinary
16:27:43 - 08-May-25
Unknown* 3,233 17.50p Ordinary
16:22:13 - 08-May-25
Sell* 26,155 17.2655p Ordinary
15:31:16 - 08-May-25
Sell* 1,807 17.25p Ordinary
15:29:39 - 08-May-25
Buy* 630 17.6777p Ordinary
15:13:00 - 08-May-25
Buy* 1,709 17.6777p Ordinary
14:46:45 - 08-May-25
Buy* 5 17.6777p Ordinary
14:38:26 - 08-May-25
Buy* 80,114 17.475p Ordinary
14:18:00 - 08-May-25
Buy* 50 17.50p SI Trade
14:18:00 - 08-May-25
Buy* 6 17.50p SI Trade
14:18:00 - 08-May-25
See more hVIVO trades

hVIVO (HVO) Share Price History

Time period:
to
Date Open High Low Close Volume
8th May 2025 (Thu) 18.00 18.00 17.25 17.50 603,343
7th May 2025 (Wed) 18.00 18.00 18.00 18.00 1,659,892
6th May 2025 (Tue) 17.75 18.40 17.75 18.40 708,713
5th May 2025 (Mon) 17.90 17.90 17.90 17.90 0
2nd May 2025 (Fri) 18.50 18.50 17.625 17.75 1,031,964
1st May 2025 (Thu) 19.00 19.25 18.25 18.50 2,701,564
30th Apr 2025 (Wed) 18.00 19.45 19.10 19.10 2,968,144
29th Apr 2025 (Tue) 17.625 18.25 17.625 18.00 1,271,474
28th Apr 2025 (Mon) 16.50 17.75 17.50 17.50 1,893,964
25th Apr 2025 (Fri) 16.25 17.00 16.50 17.00 941,645
24th Apr 2025 (Thu) 16.375 16.35 16.35 16.35 1,461,505
23rd Apr 2025 (Wed) 16.50 16.50 16.25 16.375 507,555
22nd Apr 2025 (Tue) 16.375 16.375 16.25 16.35 1,957,518
21st Apr 2025 (Mon) 16.25 16.25 16.25 16.25 0
18th Apr 2025 (Fri) 16.25 16.25 16.25 16.25 0
17th Apr 2025 (Thu) 16.625 16.625 16.25 16.25 685,555
16th Apr 2025 (Wed) 16.00 16.75 16.00 16.625 1,667,933
15th Apr 2025 (Tue) 16.25 16.40 15.75 16.40 1,368,712
14th Apr 2025 (Mon) 16.125 16.625 16.00 16.25 2,019,340
11th Apr 2025 (Fri) 15.30 16.375 15.125 16.125 3,273,331
10th Apr 2025 (Thu) 15.125 15.00 15.00 15.00 1,999,877
9th Apr 2025 (Wed) 14.25 14.80 14.50 14.60 1,288,502
See more hVIVO price history

hVIVO (HVO) Regulatory News

Date Source Headline
10th Apr 2025 7:05 am RNS Exercise of Options
10th Apr 2025 7:00 am RNS Final results
26th Mar 2025 1:51 pm RNS AIM Rule 17 and Schedule 2(g) Update
21st Mar 2025 7:00 am RNS Notice of Results
7th Mar 2025 7:00 am RNS Director/PDMR Shareholding
27th Feb 2025 7:00 am RNS Acquisition of Cryostore for up to £3.2m
17th Feb 2025 7:00 am RNS £2m hMPV characterisation study contract
5th Feb 2025 7:00 am RNS-R Shionogi reports positive RSV trial results
3rd Feb 2025 7:00 am RNS RSV contract signed with Inhalon Biopharma
31st Jan 2025 1:24 pm RNS Holding(s) in Company
See more hVIVO regulatory news

hVIVO (HVO) Share News

UK dividends calendar - next 7 days

8th May 2025 14:04

Read More

EARNINGS AND TRADING: Castelnau swings to profit; hVIVO sees growth

10th Apr 2025 17:45

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: hVIVO signs GBP2 million deal as aims to progress hMPV care

17th Feb 2025 17:54

hVIVO PLC - London-based contract research organisation testing vaccines for infectious and respiratory diseases - Signs GBP2 million contract with a new biopharmaceutical client to complete the final stage of its pilot human metapneumovirus characterisation study ahead of future hMPV human challenge trials. The final phase of the study is expected to commence in the first half of 2025, with the revenue being recognised in 2025. hVIVO expects to be in a position to commence hMPV HCTs from the second half of the year, subject to the successful completion of this study and receipt of the necessary regulatory approvals. hMPV is a common virus that causes an upper respiratory infection, similar to the common cold. Severe cases can result in bronchiolitis, bronchitis and pneumonia. Despite this, hVIVO points out there are currently no vaccines or antivirals approved to treat hMPV. Read More

hVIVO wins contract for RSV drug human trial for Inhalon Biopharma

3rd Feb 2025 16:37

(Alliance News) - hVIVO PLC on Monday said it has signed a contract with Inhalon Biopharma Inc to test its antiviral candidate to treat respiratory syncytial virus. Read More

hVIVO eyes double-digit revenue rise, announces new acquisition

29th Jan 2025 11:42

(Alliance News) - hVIVO PLC on Wednesday released an optimistic pre-annual results trading update, and said it expects "further strong growth" next year. Read More

See more hVIVO news
FTSE 100 Latest
Value8,531.61
Change-27.72

Login to your account

Forgot Password?

Not Registered